BlackRock reports 10% QIAGEN N.V. stake in ownership filing (QGEN)

Rhea-AI Filing Summary

BlackRock, Inc. reports owning 20,678,987 shares of QIAGEN N.V. common stock, representing 10.0% of the class as of January 31, 2026. BlackRock has sole voting power over 19,575,569 shares and sole dispositive power over the full 20,678,987 shares.

The filing states that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of QIAGEN. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of the outstanding common shares.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

QIAGEN N.V.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

N72482156

(CUSIP Number)

01/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. N72482156

1

Names of Reporting Persons

BlackRock, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 19,575,569.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 20,678,987.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

20,678,987.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

10.0 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: QIAGEN N.V.
(b)	Address of issuer's principal executive offices: Hulsterweg 82 PL Venlo Netherlands 5912
Item 2.
(a)	Name of person filing: BlackRock, Inc. In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release.
(b)	Address or principal business office or, if none, residence: BlackRock, Inc., 50 Hudson Yards New York, NY 10001
(c)	Citizenship: See Item 4 of Cover Page
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: N72482156
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 20678987
(b)	Percent of class: 10.0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 19575569
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 20678987
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of QIAGEN N.V.. No one person's interest in the common stock of QIAGEN N.V. is more than five percent of the total outstanding common shares.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BlackRock, Inc.

Signature:	Spencer Fleming
Name/Title:	Managing Director
Date:	02/06/2026

Exhibit Information

Exhibit 24: Power of Attorney Exhibit 99: Item 7

FAQ

How many QIAGEN N.V. shares does BlackRock Inc. report owning in this Schedule 13G for QGEN?

BlackRock Inc. reports beneficial ownership of 20,678,987 QIAGEN N.V. common shares. This stake represents 10.0% of the company’s outstanding common stock as of January 31, 2026, according to the Schedule 13G ownership disclosure.

What percentage of QIAGEN N.V. does BlackRock’s 13G filing for QGEN indicate it owns?

BlackRock’s Schedule 13G shows it beneficially owns 10.0% of QIAGEN N.V.’s common stock. This ownership level is based on 20,678,987 shares reported as of January 31, 2026, giving BlackRock a significant institutional position in the company.

What voting and dispositive powers over QIAGEN N.V. shares does BlackRock report in this 13G?

BlackRock reports sole voting power over 19,575,569 QIAGEN N.V. shares and sole dispositive power over 20,678,987 shares. It reports no shared voting or shared dispositive power, indicating centralized control of these rights within BlackRock’s reporting business units.

Does BlackRock’s Schedule 13G for QIAGEN N.V. (QGEN) indicate any intent to influence control?

BlackRock certifies the QIAGEN N.V. shares were acquired and are held in the ordinary course of business. It states they were not acquired and are not held to change or influence control of the issuer, consistent with a passive institutional ownership position.

Who ultimately benefits from the QIAGEN N.V. shares held by BlackRock according to this filing?

The filing notes that various persons have rights to dividends or sale proceeds from QIAGEN N.V. shares held by BlackRock. However, no single person’s interest relates to more than five percent of QIAGEN’s total outstanding common shares, reflecting diversified underlying clients.

What is the event date for BlackRock’s reported QIAGEN N.V. ownership in this Schedule 13G?

The Schedule 13G lists January 31, 2026 as the date of the event requiring the filing. Ownership figures such as the 20,678,987 shares and 10.0% of the class are reported as of this date for QIAGEN N.V.’s common stock.